Logo.jpg
Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer
04 nov. 2024 07h00 HE | Memo Therapeutics AG
PRESS RELEASE Frits is an industry veteran with a proven track record in nephrology drug development, including the successful development of Velphoro® and Ferinject® at Vifor Pharma Schlieren /...
Logo.jpg
Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients
01 nov. 2024 07h00 HE | Memo Therapeutics AG
Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections...
Logo.jpg
Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
27 août 2024 07h00 HE | Memo Therapeutics AG
PRESS RELEASE Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy Seasoned commercial leader with significant international experience Joins ahead of lead development candidate...
Logo.jpg
Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
27 août 2024 02h00 HE | Memo Therapeutics AG
PRESS RELEASE Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy Seasoned commercial leader with significant international experience Joins ahead of lead development candidate...
Logo.jpg
Memo Therapeutics AG appoints Paul Carter as Chairperson
08 juil. 2024 07h00 HE | Memo Therapeutics AG
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public...
Logo.jpg
Memo Therapeutics AG appoints Paul Carter as Chairperson
08 juil. 2024 02h00 HE | Memo Therapeutics AG
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and...